Calcium sensing receptor suppresses liver fibrosis by coupling TRPV4-mediated calcium influx to promote apoptosis of hepatic stellate cells

Technical Summary: Calcium Sensing Receptor Suppresses Liver Fibrosis by Coupling TRPV4-Mediated Calcium Influx to Promote Apoptosis of Hepatic Stellate Cells

Problem Statement
Liver fibrosis is a progressive pathological condition driven by the persistent activation of hepatic stellate cells (HSCs) and their resistance to apoptosis, leading to excessive extracellular matrix deposition. While the molecular mechanisms regulating HSC fate are partially understood, effective anti-fibrotic therapies remain limited. Concurrently, clinical observations indicate that hypocalcemia is prevalent in patients with advanced cirrhosis and correlates with disease severity. However, the causal link between disturbed calcium homeostasis, the calcium-sensing receptor (CaSR), and the progression of liver fibrosis remains undefined. Specifically, it is unclear whether calcium signaling directly regulates HSC survival or if the observed hypocalcemia is merely a secondary metabolic consequence of liver failure.

Methodology
The study employed a multi-faceted approach combining clinical data analysis, in vivo animal models, and in vitro cellular experiments:

• Clinical Cohort: Serum calcium levels were analyzed in a retrospective multicenter cohort of 766 individuals (patients with liver fibrosis/cirrhosis vs. controls) from hospitals in southwest China.
• Animal Models: Liver fibrosis was induced in Sprague-Dawley rats and mice using carbon tetrachloride (CCl₄). Additionally, HSC-specific CaSR conditional knockout (CaSR-cKO) mice were generated using a GFAP-Cre/loxP system to assess the receptor's role in vivo.
• Cellular Models: Human (LX-2) and rat (HSC-T6) HSCs were cultured and activated using TGF-β1 to mimic fibrotic conditions.
• Interventions: Researchers utilized CaSR agonists (extracellular CaCl₂, spermine), antagonists (NPS-2143), and specific inhibitors for TRPV4 (RN-1734), PKCα (Go6976), and calcium chelators (BAPTA-AM).
• Techniques: The study utilized Western blotting, qRT-PCR, immunohistochemistry, and immunofluorescence to assess protein expression. Functional assays included CCK-8/EdU for proliferation, TUNEL/Annexin V for apoptosis, and flow cytometry for ROS and intracellular calcium imaging (Fluo-4 AM). Co-immunoprecipitation (Co-IP) was used to verify protein-protein interactions.

Key Contributions and Results

1. Clinical and Tissue Correlation:
   Analysis of the clinical cohort revealed significantly reduced serum calcium levels in patients with liver cirrhosis compared to healthy controls. Consistently, CaSR expression was markedly downregulated in fibrotic liver tissues, activated HSCs, and experimental fibrosis models, showing an inverse correlation with the activation marker α-SMA.

2. CaSR as a Negative Regulator of Fibrosis:
   In vitro, extracellular calcium (CaCl₂) dose-dependently inhibited TGF-β1-induced HSC proliferation and α-SMA expression. This anti-fibrotic effect was abolished by the CaSR antagonist NPS-2143, confirming the dependence on functional CaSR signaling.
   In vivo, CaCl₂ administration alleviated CCl₄-induced liver injury, reducing serum transaminases and collagen deposition. Conversely, HSC-specific deletion of CaSR (CaSR-cKO) exacerbated fibrosis, confirming CaSR's endogenous protective role.

3. Mechanism of Calcium Influx via TRPV4:
   The study identified that CaSR-mediated calcium signaling in HSCs relies predominantly on extracellular calcium influx rather than intracellular store release. Pharmacological screening pinpointed TRPV4 as the specific channel mediating this influx.

   • Coupling: Co-immunoprecipitation and immunofluorescence confirmed a physical and functional coupling between CaSR and TRPV4 at the plasma membrane. This interaction was disrupted under fibrotic conditions (TGF-β1 activation).
   • Dependency: Inhibition of TRPV4 (RN-1734) blocked CaSR-mediated calcium influx and reversed the anti-fibrotic effects of calcium, indicating TRPV4 is essential for CaSR function in this context.

4. Signaling Pathway to Apoptosis:
   The CaSR-TRPV4 axis promotes the apoptosis of activated HSCs through a specific signaling cascade:

   • Upstream: CaSR activation regulates TRPV4 expression via a PKCα-dependent mechanism.
   • Downstream: Calcium influx through TRPV4 leads to Reactive Oxygen Species (ROS) accumulation.
   • Effector: ROS accumulation activates the JAK2/STAT3/NF-κB signaling pathway, shifting the Bax/Bcl-2 ratio to favor apoptosis.
   • Outcome: This pathway effectively eliminates activated HSCs, thereby limiting fibrotic progression.

Significance and Claims
The paper identifies the CaSR-TRPV4 axis as a critical, previously unrecognized signaling module that links extracellular calcium sensing to intracellular fate control in liver fibrosis. The authors claim that:

• Impaired calcium sensing is not merely a consequence of liver disease but actively contributes to fibrogenesis by preventing the apoptosis of activated HSCs.
• The disruption of the CaSR-TRPV4 complex is a key event in HSC activation.
• Restoring physiological calcium signaling, potentially through calcium supplementation or dietary intervention, represents a potential adjunctive strategy to reactivate endogenous anti-fibrotic defenses.
• This study shifts the therapeutic perspective from solely suppressing matrix production to actively reprogramming the fate of fibrogenic cells toward apoptotic clearance.

The authors acknowledge limitations, noting that the CCl₄ model does not fully replicate human metabolic or cholestatic fibrosis heterogeneity, and that the precise molecular link between ROS and JAK2/STAT3/NF-κB activation requires further investigation. However, the findings provide a mechanistic basis for the association between hypocalcemia and liver fibrosis severity.